ストックスクリーナーアプリを入手
26.28
1.82%
0.47
アフターアワーズ：
26.24
-0.04
-0.15%
前日終値:
$25.81
開ける：
$25.72
24時間の取引高:
4.99M
Relative Volume:
0.82
時価総額：
$2.96B
収益：
-
当期純損益:
$-99.15M
株価収益率:
-28.26
EPS:
-0.93
ネットキャッシュフロー:
$-74.25M
1週間 パフォーマンス:
+5.25%
1か月 パフォーマンス:
-2.85%
6か月 パフォーマンス:
+8.82%
1年 パフォーマンス:
-58.49%
1日の値動き範囲:
$25.04
$26.55
1週間の範囲:
$24.78
$26.96
52週間の値動き範囲:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
名前
Viking Therapeutics Inc
セクター
電話
858-704-4660
住所
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
26.28 | 2.90B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 開始されました | Goldman | Neutral |
| 2025-02-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-07 | 開始されました | Citigroup | Neutral |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-11-22 | 開始されました | B. Riley Securities | Buy |
| 2024-11-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-11 | 開始されました | JP Morgan | Overweight |
| 2024-06-27 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-07 | 開始されました | Jefferies | Buy |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2023-05-31 | 再開されました | ROTH MKM | Buy |
| 2023-03-28 | 繰り返されました | Maxim Group | Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 開始されました | BMO Capital Markets | Outperform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-05-01 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-25 | 開始されました | Stifel | Buy |
| 2019-03-29 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 繰り返されました | Maxim Group | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-18 | 繰り返されました | Maxim Group | Buy |
| 2018-09-18 | 繰り返されました | Raymond James | Outperform |
| 2018-07-20 | 開始されました | SunTrust | Buy |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-01 | 繰り返されました | Laidlaw | Buy |
| 2018-05-31 | 繰り返されました | Maxim Group | Buy |
| 2018-03-26 | 再開されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | Maxim Group | Buy |
| 2017-11-21 | 開始されました | ROTH Capital | Buy |
すべてを表示
Viking Therapeutics Inc (VKTX) 最新ニュース
Will Viking Therapeutics Inc. stock attract more institutional investors2025 Top Decliners & Technical Buy Zone Confirmations - newser.com
BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) With a $125 PT - Yahoo Finance
BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) - MSN
Why This Beaten-Down GLP-1 Stock Could Be a Steal - AOL.com
Why This Beaten-Down GLP-1 Stock Could Be a Steal - The Motley Fool
What to expect from Viking Therapeutics Inc. in the next 30 daysQuarterly Portfolio Summary & Long-Term Safe Investment Plans - newser.com
HC Wainwright & Co. Reiterates Viking Therapeutics (VKTX) Buy Recommendation - Nasdaq
Applying Elliott Wave Theory to Viking Therapeutics Inc.Dividend Hike & Real-Time Stock Entry Alerts - newser.com
Viking Therapeutics: Promising Position in GLP-1 Market with Strategic Growth Potential - TipRanks
VKTX: HC Wainwright Reiterates Buy Rating and Maintains Price Ta - GuruFocus
Viking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Is Viking Therapeutics Inc. reversing from oversold territoryWeekly Investment Report & Safe Capital Growth Tips - newser.com
Is Viking Therapeutics Inc. stock oversold or undervaluedJuly 2025 Catalysts & Free High Accuracy Swing Entry Alerts - newser.com
Short interest data insights for Viking Therapeutics Inc.Trade Entry Summary & Stepwise Trade Execution Plans - newser.com
Viking Therapeutics: Overdue For Gains (NASDAQ:VKTX) - Seeking Alpha
What drives Viking Therapeutics Inc 1VT stock priceResistance Breakout Alerts & Small Investment Capital Gains - earlytimes.in
Is Viking Therapeutics Inc a good long term investmentTechnical Analysis Insights & Low Risk Wealth Plans - Early Times
Using flow based indicators on Viking Therapeutics Inc.July 2025 Outlook & Weekly Return Optimization Alerts - newser.com
Analyzing Viking Therapeutics Inc. with risk reward ratio chartsVolume Spike & Weekly Watchlist for Hot Stocks - newser.com
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet? - MSN
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. - MSN
Viking Therapeutics: A Huge Reward Or A Total Loss (NASDAQ:VKTX) - Seeking Alpha
Pfizer Acquires Metsera, Viking Therapeutics’ Prospects Attract Attention - NAI500
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - sharewise.com
Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.8%Here's Why - MarketBeat
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up? - sharewise.com
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - sharewise.com
Viking Therapeutics Stock Surges on Promising Obesity Drug Pipeline - AD HOC NEWS
Viking Therapeutics (NASDAQ:VKTX) Trading 6.6% HigherTime to Buy? - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Trading 7.4% HigherWhat's Next? - MarketBeat
Viking Therapeutics : September 2025 Corporate Presentation - MarketScreener
Are Safety Concerns Around VK2735 Shaping Investor Perceptions of Viking Therapeutics (VKTX)? - simplywall.st
Why Viking Therapeutics Stock Crashed Today - aol.com
U.S. Capital Wealth Advisors LLC Purchases 27,795 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Shares Dip as Pfizer Chooses Rival Acquisition - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
Pfizer’s $5B Bet on Metsera ($MTSR) vs Viking Therapeutics ($VKTX) - MSN
Strs Ohio Invests $604,000 in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics at Bernstein Forum: Strategic Moves in Obesity Market - Investing.com
Transcript : Viking Therapeutics, Inc. Presents at Bernstein 2nd Annual Global Healthcare Conference, Sep-23-2025 11 - MarketScreener
Viking Therapeutics at Bernstein Forum: Strategic Moves in Obesity Market By Investing.com - Investing.com UK
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ - Stocktwits
Exchange Traded Concepts LLC Buys 20,296 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Oral Study Disappoints, Competitor Gets Bought Out (Rating Downgrade) - Seeking Alpha
Why Viking Therapeutics Shares Are Climbing High - TipRanks
BTIG Reiterates Buy Rating for Viking Therapeutics (VKTX) with $125 Target | VKTX Stock News - GuruFocus
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - 富途牛牛
Viking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from BTIG Research - MarketBeat
Viking Therapeutics: Strong Buy Rating Amid Strategic Positioning and Acquisition Potential in the Metabolic Disease Market - TipRanks
Viking Therapeutics (VKTX): Revisiting Valuation After Safety Concerns From Oral Obesity Drug Trial News - simplywall.st
Kingstone Capital Partners Texas LLC Invests $1.37 Million in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Inc (VKTX) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):